206 terminated. 206 Phase 2, 30 Phase 1, 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 206 | Terminated 206 |
| Phase 1 | 30 | Terminated 30 |
| Phase 3 | 18 | Terminated 18 |
Follow Glucose Metabolism Disorders: new trials by email Literature Review of Glucose Metabolism Disorders trials Research Report on Glucose Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes LY3549492, Placebo - Obesity, Overweight | Phase 2 | Terminated | Eli Lilly and Company | 1 | 2025-06-19 | 2026-08-31 |
| Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes Lyumjev 100 UNT/ML Injectable Solution, Premixed Lyumjev - Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | St. Olavs Hospital | 9 | 2025-04-01 | 2026-10-19 |
| CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes CK-0045, Placebo - Type 2 Diabetes Mellitus (T2DM), Obesity and Overweight | Phase 2 | Terminated | Cytoki Pharma | 90 | 2024-09-06 | 2026-02-20 |
| Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome MitoQ (mitoquinol mesylate), Placebo - Lower Urinary Tract Symptoms, Overactive Bladder Syndrome | Phase 2 | Terminated | Iman Al-Naggar, PhD | 20 | 2024-04-03 | 2026-05-01 |
| Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1 Glucagon - Type 1 Diabetes | Phase 2 | Terminated | St. Olavs Hospital | 9 | 2023-12-22 | 2025-06-13 |
| STOP-T1D Low-Dose (ATG) Antithymocyte Globulin, Placebo (for ATG) - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 | 2023-11-01 | 2026-05-07 |
| A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain GSK3858279, Placebo - Pain | Phase 2 | Terminated | GlaxoSmithKline | 147 | 2023-09-20 | 2025-11-21 |
| Siplizumab in T1DM Siplizumab - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2023-05-18 | 2026-07-28 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | Terminated | Alnylam Pharmaceuticals | 49 | 2023-03-10 | 2025-05-07 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients TCD601, Placebo - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | ITB-Med LLC | 9 | 2023-01-23 | 2025-08-14 |
| Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity PF-07081532, Placebo, Rybelsus - Diabetes Mellitus, Obesity | Phase 2 | Terminated | Pfizer | 902 | 2022-10-27 | 2024-08-01 |
| Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. Ladarixin, Placebo - Type 1 Diabetes | Phase 2 | Terminated | Dompé Farmaceutici S.p.A | 3 | 2022-09-14 | 2025-02-03 |
| CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients Empagliflozin10Mg Tab, Placebo - Kidney Transplant; Complications, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Duke University | 20 | 2022-07-25 | 2026-02-27 |
| The ORTIZ Study: Optimising RASi Therapy With SZC Sodium Zirconium Cyclosilicate, Placebo - CKD, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Barts & The London NHS Trust | 18 | 2022-06-17 | 2025-06-08 |
| Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis Insulin Glargine - DKA | Phase 2 | Terminated | HealthPartners Institute | 8 | 2022-05-31 | 2024-06-18 |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant Alpelisib, Fulvestrant, Metformin XR - Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 2 | 2022-04-06 | 2024-10-09 |
| A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes RGT001-075, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Terminated | Regor Pharmaceuticals Inc. | 17 | 2022-03-29 | 2023-11-18 |
| Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer 5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel - Chronic Diabetic Foot Ulcers | Phase 2 | Terminated | Lakewood-Amedex Inc | 3 | 2022-03-11 | 2024-01-30 |
| Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM MBL949, Placebo - Obesity | Phase 2 | Terminated | Novartis Pharmaceuticals | 126 | 2022-02-10 | 2024-10-09 |
Showing 20 of 206. Sign in to see all of them.
Diabetes Mellitus, Type 2 (84) · Diabetes Mellitus (75) · Diabetes Mellitus, Type 1 (52) · Insulin Resistance (19) · Obesity (19) · Hypoglycemia (14) · Metabolic Syndrome (11) · Diabetes Complications (10) · Hypertension (7) · Hyperglycemia (6) · Diabetic Nephropathies (5) · Diabetic Neuropathies (5) · Dyslipidemias (5) · Renal Insufficiency, Chronic (5)
Nutritional and Metabolic Diseases (206) · Metabolic Diseases (202) · Endocrine System Diseases (180) · Diabetes Mellitus (107) · Immune System Diseases (53) · Autoimmune Diseases (50) · Pathological Conditions, Signs and Symptoms (39) · Hyperinsulinism (29) · Signs and Symptoms (27) · Cardiovascular Diseases (23) · Vascular Diseases (23) · Body Weight (20) · Nutrition Disorders (19) · Overnutrition (19)
Metformin (17) · Insulin (10) · Insulin Aspart (8) · Insulin, Regular, Human (5) · Pioglitazone (5) · Antilymphocyte Serum (4) · Sodium Chloride (4) · Fatty Acids, Omega-3 (3) · Liraglutide (3) · Sitagliptin Phosphate (3) · dapagliflozin (3) · tesaglitazar (3) · thymoglobulin (3) · 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide (2) · Cholecalciferol (2)
Merck Sharp & Dohme LLC (8) · Florida Atlantic University (7) · Pfizer (7) · Eli Lilly and Company (6) · AstraZeneca (5) · GlaxoSmithKline (5) · Novartis Pharmaceuticals (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Novartis (3) · Takeda (3) · University of Minnesota (3) · Albert Einstein College of Medicine (2) · DiObex (2) · Dompé Farmaceutici S.p.A (2)
United States (139) · Canada (21) · Germany (15) · Italy (13) · United Kingdom (12) · Australia (10) · Hungary (9) · France (8) · Japan (8) · Poland (8) · Israel (7) · Spain (7) · Argentina (6) · Belgium (6) · Czechia (6)
Betty Tuller, Ph.D (3) · Betty Tuller, PhD (3) · Dariush Elahi, PhD (2) · Gary L Pierce, PhD (2) · Meredith Hawkins, M.D., M.S. (2) · Abhay Mutha, MD (1) · Adis Keric, PharmD (1) · Ajna Hamidovic, PharmD, MS (1)
PMID 39952695, PMID 11852377, PMID 12037511, PMID 12448827, PMID 12746623, PMID 12846028, PMID 15030519, PMID 15885816, PMID 17276373, PMID 18032779, PMID 18434652, PMID 18752857, PMID 19005394, PMID 19190233, PMID 19443276, PMID 19475464, PMID 21423999, PMID 21799479, PMID 21994424, PMID 22496216, PMID 22522612, PMID 22689694, PMID 23129601, PMID 23412700, PMID 23483886, PMID 23570538, PMID 23734252, PMID 23848826, PMID 24075453, PMID 24408401, PMID 24482677, PMID 24622416, PMID 25081992, PMID 25240532, PMID 25666761, PMID 25816117, PMID 25968622, PMID 26068866, PMID 26166259, PMID 26981940, PMID 27053235, PMID 27208317, PMID 27271183, PMID 27470878, PMID 27871675, PMID 28191913, PMID 28198767, PMID 28325826, PMID 28605608, PMID 28860128
2017 (3), 2009 (2), 2016 (2), 2005 (1), 2008 (1), 2018 (1), 2023 (1), K23DK114477 (1), P30AG067988 (1), R01DK056953 (1), R01DK061644 (1), R01DK069861 (1), R01DK079974 (1), UC4DK117009-01 (1), UL1RR024150 (1)